Elsevier

Neuroscience Letters

Volume 169, Issues 1–2, 14 March 1994, Pages 179-180
Neuroscience Letters

APOE genotype does not modulate age of onset in families with chromosome 14 encoded Alzheimer's disease

https://doi.org/10.1016/0304-3940(94)90385-9Get rights and content

Abstract

A recent study has demonstrated an association of the apolipoprotein E allele ɛ4 (APOE*4) to familial and sporadic late-onset Alzheimer's disease (AD). Also, in late-onset AD families linked to chromosome 19, the onset age decreased when the number of APOE*4 alleles increased. A similar effect of the APOE*4 genotype was observed in early-onset AD families linked to mutations in the APP gene located on chromosome 21. We assessed whether the APOE genotype had an influence on the age of onset of AD in chromosome 14 linked early-onset AD families. No significant effect of the APOE genotype on onset age could be detected.

References (15)

  • WenhamP.R. et al.

    Apolipoprotein E genotyping by one-stage PCR

    Lancet

    (1991)
  • CorderE.H. et al.

    Gene dose of Apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families

    Science

    (1993)
  • Haan J., Van Broeckhoven C., van Duijn, C. M., Voorhoeve, E., van Harskamp F., van Swieten J.C., Maat-Schieman, M.L.C.,...
  • HardyJ.

    Framing beta-amyloid

    Nature Genet.

    (1992)
  • HouldenH. et al.

    ApoE genotype and Alzheimer's disease

    Lancet

    (1993)
  • HouldenH. et al.

    Confirmation that the Apolipoprotein E, E4 allele is associated with late onset, familial Alzheimer's disease

    Neurodegeneration

    (1993)
  • MartinJ.J. et al.

    Early-onset Alzheimer's disease in 2 large Belgian families

    Neurology

    (1991)
There are more references available in the full text version of this article.

Cited by (124)

  • Experimental modelling of Alzheimer's disease for therapeutic screening

    2022, European Journal of Medicinal Chemistry Reports
  • A novel presenilin 1 mutation (Ala275Val) as cause of early-onset familial Alzheimer disease

    2014, Neuroscience Letters
    Citation Excerpt :

    ApoE is a susceptibility gene that is frequently found in EO-AD and LO-AD cases [34]. However, in PSEN1 mutation carriers, the ApoE ε4 genotype is typically not the determining factor in EO-AD [35], and studies suggest that the ApoE ε4 allele rather has its maximum impact in patients between the ages of 60 and 70 years [36]. As the patient reported a positive family history of early-onset dementia, we were able to detect the same Ala275Val mutation in the DNA of the patient's father demonstrating the cosegregation with a similar disease.

  • Genetics of Alzheimer Disease

    2013, Emery and Rimoin's Principles and Practice of Medical Genetics
  • γ-secretases: from cell biology to therapeutic strategies

    2010, The Lancet Neurology
    Citation Excerpt :

    The reason why PSEN2 mutations manifest at an older age than do PSEN1 mutations is unclear, and further work on the differential tissue distribution or the reported differences79,80 in molecular properties of PSEN2 or γ-secretase might yield an explanation. In contrast to sporadic Alzheimer's disease, no major modifiers of age at onset have been identified in patients with early-onset familial disease.81,82 The only modifier suggested in families with early-onset disease is the HLA-2 genotype, but the precise mechanism is unclear.83,84

  • Linking Aβ and Tau in Late-Onset Alzheimer's Disease: A Dual Pathway Hypothesis

    2008, Neuron
    Citation Excerpt :

    As a corollary in living subjects, cerebral spinal fluid (CSF) studies have also found an association between APOE4 genotype and both Aβ (Galasko et al., 1998; Sunderland et al., 2004) and phospho-tau levels (Glodzik-Sobanska et al., 2007; Golombowski et al., 1997). Although FTD caused by tau mutations does not appear to be robustly influenced by APOE4 genotype (Houlden et al., 1999; Pickering-Brown et al., 2000), it is plausible that the mutations override the impact of APOE4, similar to the lack of APOE4's effect in AD patients with presenilin mutations (Van Broeckhoven et al., 1994). In support of this, in one study relatively young nondemented individuals (mean = 44), unlikely to have plaques or Aβ pathology, were found to have more tangles in the entorhinal area if they were APOE4 positive (Ghebremedhin et al., 1998).

View all citing articles on Scopus
View full text